Flumazenil - Expansion Therapeutics
Alternative Names: ERX-963; Flumazenil intravenous - Expansion TherapeuticsLatest Information Update: 28 Jun 2022
At a glance
- Originator The Scripps Research Institute
- Class Antidotes; Benzodiazepinones; Esters; Fluorine compounds; Imidazoles; Small molecules
- Mechanism of Action RNA-binding protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Myotonic dystrophy
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for phase-I development in Myotonic dystrophy in USA (IV)
- 17 Apr 2021 Safety and efficacy data from phase I trial in Myotonic dystrophy presented at 73rd Annual Meeting of the American Academy of Neurology (AAN-2021)
- 30 Apr 2020 Expansion Therapeutics completes a phase I trial in Myotonic dystrophy in USA (NCT03959189)